Gri-Cel S.A.

Overview

Gri-Cel S.A. is a private investment firm dedicated to advancing research and development in the fields of advanced therapies and personalized medicine. As a subsidiary of Grifols, a global leader in plasma-derived therapeutics, Gri-Cel focuses on investments that align with Grifols' strategic interests in innovative medical solutions. The firm has been instrumental in supporting various biotechnology companies, particularly those specializing in cell therapy and regenerative medicine. One of Gri-Cel's notable investments includes a €12 million capital increase in TiGenix, a Belgian biotechnology company specializing in cell therapy. This investment facilitated TiGenix's clinical trials for treatments targeting perianal fistulae in Crohn's disease patients. Additionally, Gri-Cel acquired a 40% equity share in VCN Biosciences, a Catalan firm dedicated to developing oncolytic adenoviruses for cancer treatment, and a 51% stake in Araclon Biotech, a company focused on Alzheimer's disease diagnostics and vaccine development. Through these strategic investments, Gri-Cel S.A. demonstrates its commitment to fostering innovation in the biotechnology sector, particularly in areas with significant unmet medical needs. The firm's approach emphasizes collaboration with emerging companies to accelerate the development of cutting-edge therapies, thereby contributing to advancements in healthcare and patient outcomes.